Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIBW2
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
**BIBW2** is an investigational allogeneic therapeutic melanoma cell vaccine developed by Boehringer Ingelheim for advanced malignant melanoma. The phase 1 study evaluated intradermal administration of vaccine components containing allogeneic melanoma cells, including an IL-2-secreting cell component generated by transfection with the human interleukin-2 gene. The intended mechanism was to present shared melanoma-associated antigens while providing local IL-2-mediated immune stimulation at the injection site, thereby augmenting tumor-specific host immune responses. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02203864))
- Other names
- BIWB 2BIWB2BIWB-2
Beyond the preview
Go deeper on BIBW2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIBW2.